Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Critical care management as part of oncological therapy].

Deutsche medizinische Wochenschrift (1946)·2026
Same author

Conference on challenges in sarcoma (CCS) 2024: Expert opinions on non-evidence-based management aspects.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Glioblastoma in the oldest old: Clinical characteristics, therapy, and outcome in patients aged 80 years and older.

Neuro-oncology practice·2024
Same author

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.

The journal of pathology. Clinical research·2024
Same author

A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.

European journal of cancer (Oxford, England : 1990)·2023
Same author

MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value.

Acta neuropathologica communications·2023

Related Experiment Video

Updated: May 23, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Intrathecal trastuzumab: dose matters

Silvia Hofer, Karin Mengele, Hans Joachim Stemmler

    Acta Oncologica (Stockholm, Sweden)
    |April 25, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
    13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
    06:25

    High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

    Published on: June 14, 2021

    Related Experiment Videos

    Last Updated: May 23, 2026

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
    13:59

    High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

    Published on: August 18, 2023

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
    13:19

    Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

    Published on: April 26, 2024

    High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
    06:25

    High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

    Published on: June 14, 2021